Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medical Oncology | 2 | 2021 | 243 | 0.790 |
Why?
|
| Neoplasms | 3 | 2023 | 2942 | 0.790 |
Why?
|
| HIV Infections | 4 | 2022 | 2020 | 0.780 |
Why?
|
| Hematologic Diseases | 2 | 2025 | 82 | 0.770 |
Why?
|
| Thrombocytosis | 1 | 2022 | 33 | 0.760 |
Why?
|
| Healthcare Disparities | 2 | 2024 | 481 | 0.750 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 235 | 0.690 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 235 | 0.670 |
Why?
|
| Cerebellar Neoplasms | 1 | 2024 | 461 | 0.650 |
Why?
|
| Medulloblastoma | 1 | 2024 | 571 | 0.620 |
Why?
|
| Malnutrition | 1 | 2022 | 220 | 0.620 |
Why?
|
| Anemia | 1 | 2022 | 350 | 0.580 |
Why?
|
| Hematology | 1 | 2018 | 43 | 0.580 |
Why?
|
| Immunophenotyping | 1 | 2018 | 344 | 0.560 |
Why?
|
| Global Health | 2 | 2021 | 612 | 0.520 |
Why?
|
| Child | 22 | 2025 | 25779 | 0.520 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2021 | 570 | 0.510 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 816 | 0.500 |
Why?
|
| Flow Cytometry | 1 | 2018 | 806 | 0.500 |
Why?
|
| Africa South of the Sahara | 5 | 2025 | 117 | 0.470 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.470 |
Why?
|
| Uganda | 3 | 2024 | 86 | 0.410 |
Why?
|
| Anemia, Sickle Cell | 3 | 2022 | 344 | 0.410 |
Why?
|
| Lamivudine | 2 | 2022 | 25 | 0.390 |
Why?
|
| Capacity Building | 2 | 2025 | 24 | 0.380 |
Why?
|
| Developing Countries | 2 | 2024 | 287 | 0.340 |
Why?
|
| Pediatrics | 2 | 2025 | 1215 | 0.330 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 241 | 0.290 |
Why?
|
| Humans | 27 | 2025 | 132045 | 0.250 |
Why?
|
| Case-Control Studies | 3 | 2022 | 3421 | 0.250 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2022 | 234 | 0.230 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2016 | 169 | 0.230 |
Why?
|
| Acute Kidney Injury | 2 | 2022 | 673 | 0.220 |
Why?
|
| Retrospective Studies | 6 | 2024 | 17307 | 0.200 |
Why?
|
| Nevirapine | 1 | 2022 | 15 | 0.200 |
Why?
|
| Prognosis | 2 | 2022 | 4991 | 0.200 |
Why?
|
| Platelet Count | 1 | 2022 | 139 | 0.190 |
Why?
|
| Risk Factors | 5 | 2022 | 10834 | 0.180 |
Why?
|
| Pancytopenia | 1 | 2021 | 41 | 0.180 |
Why?
|
| Injection Site Reaction | 1 | 2021 | 7 | 0.170 |
Why?
|
| Child, Preschool | 8 | 2024 | 14821 | 0.160 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 225 | 0.160 |
Why?
|
| Rituximab | 1 | 2021 | 165 | 0.160 |
Why?
|
| Global Burden of Disease | 1 | 2019 | 32 | 0.160 |
Why?
|
| Bone Marrow Cells | 1 | 2021 | 263 | 0.160 |
Why?
|
| Anaphylaxis | 1 | 2021 | 87 | 0.160 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 149 | 0.160 |
Why?
|
| Immunologic Factors | 1 | 2021 | 185 | 0.160 |
Why?
|
| Neutropenia | 1 | 2021 | 205 | 0.150 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 141 | 0.150 |
Why?
|
| Wilms Tumor | 1 | 2019 | 118 | 0.140 |
Why?
|
| Patient Care | 1 | 2018 | 98 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Poverty | 1 | 2021 | 435 | 0.130 |
Why?
|
| Incidence | 3 | 2020 | 3362 | 0.130 |
Why?
|
| Adolescent | 8 | 2024 | 20513 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 519 | 0.130 |
Why?
|
| Lymphoma | 2 | 2021 | 331 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 251 | 0.130 |
Why?
|
| Male | 12 | 2024 | 64891 | 0.130 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 221 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 655 | 0.120 |
Why?
|
| Air Pollutants, Radioactive | 1 | 2015 | 5 | 0.120 |
Why?
|
| Radon | 1 | 2015 | 10 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 1113 | 0.120 |
Why?
|
| Infant | 6 | 2021 | 13112 | 0.120 |
Why?
|
| Air Pollution, Indoor | 1 | 2015 | 34 | 0.120 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 453 | 0.120 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 322 | 0.120 |
Why?
|
| Young Adult | 5 | 2021 | 9934 | 0.120 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 281 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 1346 | 0.110 |
Why?
|
| Female | 11 | 2024 | 70672 | 0.110 |
Why?
|
| Sarcoma, Kaposi | 1 | 2016 | 131 | 0.110 |
Why?
|
| Hodgkin Disease | 1 | 2016 | 304 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 564 | 0.100 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 1758 | 0.100 |
Why?
|
| Pericardial Effusion | 1 | 2012 | 71 | 0.090 |
Why?
|
| Stomatitis, Aphthous | 1 | 2011 | 3 | 0.090 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2012 | 153 | 0.090 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2012 | 127 | 0.090 |
Why?
|
| Atrioventricular Block | 1 | 2011 | 46 | 0.090 |
Why?
|
| Creatinine | 2 | 2022 | 414 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 237 | 0.080 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 377 | 0.070 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 1407 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1960 | 0.070 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 1444 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 2 | 2021 | 675 | 0.060 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 1083 | 0.050 |
Why?
|
| Lipocalins | 1 | 2022 | 29 | 0.050 |
Why?
|
| Lipocalin-2 | 1 | 2022 | 32 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2022 | 50 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 76 | 0.040 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2021 | 18 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 12 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 120 | 0.040 |
Why?
|
| Agammaglobulinemia | 1 | 2021 | 44 | 0.040 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2021 | 36 | 0.040 |
Why?
|
| Nephrotic Syndrome | 1 | 2021 | 51 | 0.040 |
Why?
|
| Biomarkers | 2 | 2022 | 3386 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 183 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 54 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 151 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 197 | 0.040 |
Why?
|
| Vincristine | 1 | 2020 | 195 | 0.040 |
Why?
|
| Encephalitis | 1 | 2021 | 118 | 0.040 |
Why?
|
| Resource Allocation | 1 | 2019 | 53 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 105 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 277 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 538 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 615 | 0.040 |
Why?
|
| Social Class | 1 | 2019 | 207 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 425 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2021 | 212 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 542 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2021 | 1256 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 854 | 0.030 |
Why?
|
| Texas | 2 | 2016 | 3647 | 0.030 |
Why?
|
| Multiple Sclerosis | 1 | 2021 | 383 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6411 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2020 | 342 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2018 | 355 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1539 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 312 | 0.030 |
Why?
|
| Mexico | 1 | 2016 | 185 | 0.030 |
Why?
|
| Herpesvirus 8, Human | 1 | 2016 | 50 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2020 | 8501 | 0.030 |
Why?
|
| Inhalation Exposure | 1 | 2015 | 36 | 0.030 |
Why?
|
| Housing | 1 | 2015 | 54 | 0.030 |
Why?
|
| Survival Rate | 1 | 2019 | 2161 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1097 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 1287 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 556 | 0.030 |
Why?
|
| Disease Progression | 1 | 2020 | 2228 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 763 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 1580 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 3067 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 4544 | 0.020 |
Why?
|
| Adult | 3 | 2018 | 31576 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 86 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2021 | 5142 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 127 | 0.020 |
Why?
|
| Exercise Test | 1 | 2011 | 257 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2011 | 182 | 0.020 |
Why?
|
| Heart Rate | 1 | 2011 | 576 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 474 | 0.020 |
Why?
|
| Echocardiography | 1 | 2012 | 1102 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2011 | 991 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 3196 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 2153 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12882 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 1162 | 0.010 |
Why?
|
| United States | 1 | 2016 | 11620 | 0.010 |
Why?
|